Since 1977, the World Health Organization rules and updates the list of drugs, which he calls "necessary". They are asking the government, especially in developing countries, to make the drug widely available. Adding to the list of drugs from & # 39 is controversial, because it can increase access but also puts new demands on health care budgets.
This week, the WHO added to its list of 12 drugs for five cancer treatments for cancer, including several new and high prices.
In the past, the list of WHO was focusing almost entirely on the essential drugs cheap medications. In recent years, especially with drugs for HIV, hepatitis and recently, cancer and autoimmune diseases, there is pressure on the inclusion of new drugs, some of them very expensive. This creates a problem for public health budgets, because their use could potentially divert resources from more cost-effective methods of treatment.
However, as we have seen as a result of the treatment of HIV and hepatitis, governments can reduce the price of drugs through the voluntary licensing of patent rights in commercial drug, or a forced through compulsory licensing or price controls.
My partner and partner, my co-author alive because access to effective drugs against cancer. One of these drugs was added only this week in the WHO list. Two other drugs that are used my partner, have been rejected, even though they are considered to be effective treatment.
We call on the WHO to develop a second list of drugs – those that will be marked as "important" when they are available at affordable prices.
Some of the newly added essential drugs against cancer are available at relatively low prices, in some countries, or they can be manufactured inexpensively. Afatsiniba cost of production, which is used for the treatment of lung cancer, is estimated at $ 8.85 per month, and lenalidamid for the treatment of multiple myeloma is $ 2.55 per month.
Patents block competition and impede the entry of cheap medicines in many countries. But governments can and should eliminate these bar & # 39; EASURES. Earlier, the authorities have shown that they are ready to use compulsory licensing, drug companies have responded by offering voluntary licensing of drugs through patent pool is maintained by the United Nations.
But this rarely happens outside of infectious diseases such as HIV, tuberculosis and hepatitis. In 2016, Andrew Vita, the then chief executive of GSK, said the company will consider the issue of granting patents on new drugs of MPP, but his successor is not carried out with the help of cancer drugs.
Our request necessary to make these new cancer drugs available in developing countries, causing concern that the low prices will restrain spending on research and development of new drugs. But most of today's drug sales are made in high-income countries, and profits from developing countries, for many cancer drugs it does not matter.
These fears of innovative incentives do not need to endure high prices and unequal access from us. They could be solved by other measures, eliminates the cost of research on drug prices, including grants program for scientific research or "awards at the entry into the market", providing payments for the development of drugs that meet specific needs.
We also call on the WHO to change its approach to the drugs that lyachats metastatic cancer. of essential drugs, the Committee rejected the inclusion of two important drugs used in the treatment of metastatic breast cancer, saying that it is not considered a priority.
This contradicts evidence that cancer is often manifested in low-income countries, where cancer develops further. In addition, as first-line treatment improves and prolongs life, it creates a need for the treatment of cancer, which has metastasized.
Author of the chapter of the International ecological knowledge. Helen 'Hohen, the first director of the patent medicines pool and director of the law and drug policy, have contributed